Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.40 USD
Change Today -0.0097 / -2.37%
Volume 207.1K
DCTH On Other Exchanges
Symbol
Exchange
DCTH is not on other exchanges.
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

delcath systems inc (DCTH) Snapshot

Open
$0.39
Previous Close
$0.41
Day High
$0.42
Day Low
$0.39
52 Week High
09/15/14 - $2.78
52 Week Low
08/26/15 - $0.36
Market Cap
8.7M
Average Volume 10 Days
294.0K
EPS TTM
$-1.28
Shares Outstanding
21.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DELCATH SYSTEMS INC (DCTH)

delcath systems inc (DCTH) Related Businessweek News

No Related Businessweek News Found

delcath systems inc (DCTH) Details

Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe. Its primary focus is on the execution of its clinical development program in ocular melanoma liver metastases, intrahepatic cholangiocarncinoma, hepatocellular carcinoma, and certain other cancers that are metastatic to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.

25 Employees
Last Reported Date: 03/11/15
Founded in 1988

delcath systems inc (DCTH) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $401.3K
Executive Chairman
Total Annual Compensation: $40.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $233.1K
Executive Vice President of Regulatory Affair...
Total Annual Compensation: $284.3K
Compensation as of Fiscal Year 2014.

delcath systems inc (DCTH) Key Developments

Delcath Systems Receives Non-Compliance Notice From NASDAQ

On August 11, 2015, Delcath Systems, Inc. received a notification letter from The NASDAQ Stock Market (NASDAQ) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The NASDAQ Capital Market pursuant to NASDAQ Marketplace Rule 5550(a)(2). The Notice has no effect on the listing of the Company’s common stock at this time and the Company’s common stock will continue to trade on The NASDAQ Capital Market. The Notice also stated that the Company will be provided 180 calendar days, or until February 8, 2016, to regain compliance with the Minimum Bid Price Rule. To do so, the bid price of the Company’s common stock must close at or above $1.00 per share for a minimum of ten consecutive business days prior to that date. If, by February 8, 2016, the Company cannot demonstrate compliance with Marketplace Rule 5550(a)(2), then the NASDAQ staff will determine whether or not the Company meets The NASDAQ Capital Market initial listing criteria set forth in NASDAQ Marketplace Rule 5550, except for the bid price requirement. If the Company meets the initial listing criteria (with the exception of the bid price requirement) and provides written notice of its intention to cure the deficiency during the second compliance period, the NASDAQ staff will notify the Company that it has been granted an additional 180 calendar day compliance period. If the Company is not eligible for an additional 180-day compliance period, the NASDAQ staff will provide written notice that the Company’s securities will be delisted. At that time, the Company may appeal the NASDAQ staff’s determination to delist its securities to a Listing Qualifications Panel.

Delcath Systems, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Delcath Systems, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. Total revenue for the second quarter of 2015 of $0.5 million increased 85.7% from $0.3 million for the second quarter of 2014. The Company recorded a net loss for the second quarter of 2015 of $3.7 million or $0.30 per diluted share, a decrease of $0.9 million or 19.6%, compared with a net loss of $4.6 million or $0.52 per diluted share for the same period in 2014. This decrease is primarily due to a $2.1 million reduction in operating expenses, a $0.1 million improvement in gross profit and a $1.3 million change in the fair value of the warrant liability, a non-cash item. Operating loss was $3.623 million compared to $5.904 million a year ago. Total revenue for the first half of 2015 of $0.9 million increased 62.2% from $0.6 million for the first half of 2014. The Company recorded a net loss for the first half of 2015 of $7.2 million or $0.62 per diluted share, a decrease of $2.7 million or 27.2% compared with a net loss of $9.9 million or $1.08 per diluted share for the same period in 2014. This decrease is primarily due to a $3.4 million reduction in operating expenses, a $0.2 million improvement in gross profit and a $0.9 million change in the fair value of the warrant liability, a non-cash item. Operating loss was $7.332 million compared to $10.964 million a year ago.

Delcath Receives Orphan Drug Designation from FDA for Melphalan to Treat Cholangiocarcinoma

Delcath Systems, Inc. announced that the U.S. Food and Drug Administration(FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma. The OOPD is tasked with evaluating the scientific and clinical data submissions from sponsors to identify and designate products as promising for rare diseases and to further advance scientific development of such promising medical products. Intrahepatic cholangiocarcinoma (ICC), a sub-category of cholangiocarcinoma, is a tumor in the bile duct that arises within the liver. It is the second most common primary liver tumor and represents approximately 15% of new HCC cases diagnosed annually. Surgical resection, the standard of care, is not possible for an estimated 80% to 90% of patients diagnosed with ICC. The Company recently announced the expansion of its global Phase 2 clinical study in primary liver cancer (HCC) to include an ICC cohort, which is investigating the safety and efficacy of Melphalan/HDS treatment in patients with unresectable ICC confined to the liver. The study is being conducted at the same hospitals in Europe participating in the Company's Phase 2 HCC trial, and is expected to enroll 11 patients. The ICC cohort will evaluate tumor response (objective response rate) as measured by modified Response Evaluation Criteria in Solid Tumor (mRECIST), and will assess progression-free survival and safety. Additional analyses will be conducted to characterize the systemic exposure of melphalan administered by Melphalan/HDS, as well as to assess patient-reported clinical outcomes, or quality-of-life.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DCTH:US $0.40 USD -0.0097

DCTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $14.67 USD +0.09
CTI BioPharma Corp $1.60 USD +0.03
Curis Inc $2.59 USD +0.09
Exact Sciences Corp $22.34 USD +0.15
Sirtex Medical Ltd A$34.69 AUD +0.22
View Industry Companies
 

Industry Analysis

DCTH

Industry Average

Valuation DCTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.5x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELCATH SYSTEMS INC, please visit www.delcath.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.